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Abstract
Checkpoint inhibitors are increasingly being used in clini-
cal practice. They can cause various gastrointestinal, 
hepatic and pancreatic side effects. As these side effects 
can be serious, appropriate management is essential. 
The different checkpoint inhibitors with their mechanisms 
of action and indications, as well as evaluation and man-
agement of gastrointestinal, hepatic and pancreatic side 
effects, are discussed in this article.
Key words: Checkpoint inhibitors; Immunotherapy; 
Gastrointestinal management; Hepatic and pancreatic side 
effects
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Checkpoint inhibitors are a kind of immuno-
therapy used in the treatment of various malignancies. 
Nevertheless, they carry the risk of causing different 
immune-related side effects. Physicians should be vigilant 
in recognizing and appropriately managing these side 
effects for a better outcome.
Ahmed M. Checkpoint inhibitors: what gastroenterologists need 
to know. World J Gastroenterol 2018; 24(48): 5433-5438   
URL: https://www.wjgnet.com/1007-9327/full/v24/i48/5433.htm 
DOI: https://dx.doi.org/10.3748/wjg.v24.i48.5433
INTRODUCTION
Checkpoint inhibitors have emerged as one of the most 
promising modalities of anti-cancer therapy[1]. They are 
monoclonal antibodies that block the checkpoint proteins 
either on T cells or cancer cells to enhance immune 
response against tumor cells[2]. Normally, when our body 
recognizes cancer cells or foreign bodies, our innate 
immune system (macrophages, dendritic cells, natural 
killer cells, mast cells, neutrophils, eosinophils and 
basophils) tries to eliminate them. Then, our adaptive 
immune system (B lymphocytes and T lymphocytes) 
starts working via antigen presenting cells. Checkpoint 
molecules are proteins that control specific cellular 
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processes to prevent errors. Some immune checkpoint 
proteins help the T cells to remain active, particularly 
in case of infection, whereas other immune checkpoint 
proteins regulate the immune system negatively by 
directing the T cells to switch off. Some cancer cells 
synthesize high levels of such immune checkpoint 
proteins, which can switch off the T cells and, as a result, 
the T cells can neither recognize nor kill the cancer cells.
Some of the common checkpoint proteins include: 
(1) Cytotoxic T lymphocyte-associated antigen 4 
(CTLA-4) receptors on CD4 and CD8 T lymphocytes; (2) 
programmed cell death protein 1 (PD-1) receptors on 
the surface of T cells, B cells, natural killer (NK) cells, 
monocytes and dendritic cells; and (3) programmed 
cell death protein ligand 1 (PD-L1) and programmed 
cell death protein ligand 2 (PD-L2) proteins on healthy 
tissues, hematopoietic cells and tumor cells.
When interactions between the PD-1 receptors and 
PD-L1 (also known as B7-H1) or PD-L2 (also known 
as B7-H2) occurs, it promotes exhaustion of peripheral 
effector T cells, conversion of effector T cells to regulatory 
T (Treg) cells and inhibition of tumor cell apoptosis[3]. 
Some cancer cells are able to produce PD-L1 and PD-L2 
on their surfaces to prevent any immunological attack.
CTLA-4 becomes activated by binding to B7-1 (also 
known as CD80) and B7-2 (also known as CD86) 
on antigen presenting cells (APCs), and then inhibits 
T cell activation at a proximal step in the immune 
response. On the other hand, PD-1 limits effector T 
cell function by linking with PD-L1 or PD-L2 in the later 
stages of the immune response. In the process of 
carcinogenesis, these immunosuppressive molecules are 
overexpressed[4]. Checkpoint inhibitors are monoclonal 
antibodies against PD-1, PD-L1 or CTLA-4 proteins. 
They act as a form of immunotherapy by blocking the 
immunosuppressive molecules that otherwise inhibit 
the immune system from attacking cancer cells. As a 
consequence, there is an immunological boost against 
cancer cells[5]. As they target T cells instead of cancer 
cells, they can be used in various malignancies[6]. A 
combination of checkpoint inhibitors may give a better 
anti-tumor response. There was a 23% response rate for 
metastatic non-small cell lung cancer after administration 
of durvalumab and tremelimumab[7].
Few checkpoint molecules have been discovered 
recently. These include TIM-3, LAG3, TIGIT and BTLA.
T cell immunoglobulin and mucin domain 3 (TIM-3) 
is present on the surface of CD4 T cells, CD8 T cells, 
regulatory T cells and innate immune cells (dendritic 
cells, macrophages and natural killer cells). TIM-3 binds 
to specific ligands: galectin (Gal-9), phosphatidyl serine 
(PtdSer), high-mobility group box-1 protein (HMGB) 
and carcinoembryonic antigen-related cell adhesion 
molecule 1 (CEACAM1). These interactions generate a 
variety of effects, including effector T cell apoptosis, T cell 
suppression, suppression of the innate immune response 
against tumor cells, suppression of anti-tumor activity 
and promotion of tumor growth[8]. TIM-3 is upregulated 
in patients with malignancy. In pre-clinical studies, TIM-3 
monoclonal antibody monotherapy showed modest 
anti-tumor activities[9], but combinations of anti-TIM-3 
and anti-PD-1/PD-L1 monoclonal antibodies produced 
significant anti-tumor responses against a variety of 
malignancies, including colon cancer, lung cancer, ovarian 
cancer, melanoma, lymphoma, acute myelogenous leuke-
mia and sarcoma[10]. 
LAG-3 (lymphocyte activation gene-3 protein) is an 
inhibitory receptor expressed on CD4-positive T-lympho-
cytes, CD8-positive T-lymphocytes, NK cells and B cells, 
as well as on plasmacytoid dendritic cells[11-13]. LAG-3 
inhibits both activation and proliferation of T cells[14,15]. 
Anti-LAG3 monoclonal antibodies can bind to the LAG-3 
present on tumor infiltrating lymphocytes (TILs), and 
prevent their binding to MHC (major histocompatibility 
complex) class Ⅱ molecules expressed on tumor cells. 
This may lead to activation of antigen-specific T lympho-
cytes and cytotoxic T cell-mediated tumor lysis. Clinical 
trials were done with different types of LAG-3 monoclonal 
antibodies (IMP321) on various malignancies, such as 
metastatic renal cell cancer, breast cancer, unresectable 
pancreatic cancer, as well as advanced and unresectable 
melanoma[16].
T cell immunoreceptors with Ig and ITIM domains 
(TIGIT) are inhibitory immunoreceptors present on 
some T cells (CD4, CD8), NK cells and Treg cells that 
contain Ig and immunoreceptor tyrosine-based inhibitory 
motif (ITIM) domains. TIGIT ligands include CD155 and 
CD112. In certain malignancies, CD155 and CD112 are 
highly expressed on macrophages and dendritic cells. 
TIGIT ligation leads to inhibition of T cell proliferation 
and suppression of the cytolytic function of NK cells[17]. 
Anti-tumor activity is suppressed by TIGIT, primarily 
via Treg cells and not CD8-positive T cells[18]. Anti-TIGIT 
monoclonal antibodies as a monotherapy or in com-
bination with anti-PD-L-1 antibodies have shown anti-
tumor activity[19] in phase Ⅰ/Ⅱ trials. 
BTLA (a B and T lymphocyte attenuator, also known 
as CD272) is an inhibitory protein functionally and 
structurally similar to CTLA-4 and PD-1. It is mainly 
expressed on immune cells, NK cells, dendritic cells 
and splenic macrophages. BTLA acts as a ligand for 
tumor necrosis factor receptor superfamily member 14 
(TNFRSF-14), also known as herpes virus entry mediator 
(HVEM). 
BTLA/HVEM complex inhibits T cell activation and 
proliferation[20]. BTLA is overexpressed in certain malig-
nancies like leukemia and melanoma. In mouse models, 
BTLA neutralizing antibodies limited tumor growth[21]. 
Anti-human BTLA monoclonal antibodies are currently in 
development.
CURRENT CHECKPOINT INHIBITORS
Current checkpoint inhibitors, with their indications and a 
schematic diagram (Figure 1), are mentioned below[22-28], 
including CTLA-4 blockers, PD-1 inhibitors, and PD-L1 
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inhibitors.
CTLA-4 blockers 
Ipilimumab: Indications include melanoma with lymph 
node involvement, advanced melanoma, non-small cell 
and small cell lung cancer, advanced renal cell cancer, 
and hormone refractory prostate cancer. Great success 
with durable clinical benefit was seen with nivolumab plus 
ipilimumab combination when given in DNA mismatch 
repair-deficient/microsatellite instability-high metastatic 
colorectal cancer[29].
Tremelimumab: This drug is undergoing human clinical 
trials for the treatment of various malignancies, but is 
not yet approved by the United States Food and Drug 
Administration (FDA). 
PD-1 inhibitors
Nivolumab: Indications are melanoma with lymph node 
involvement, unresectable or metastatic melanoma, 
advanced renal cell carcinoma, advanced or metastatic 
urothelial cancer, metastatic non-small cell lung cancer 
and small cell lung cancer with progression after 
platinum-based chemotherapy, refractory classical 
Hodgkin lymphoma, recurrent or metastatic squamous 
cell cancer of head and neck, microsatellite instability-
high or mismatch repair-deficient colorectal cancer, and 
hepatocellular carcinoma.
Pembrolizumab: Indications include unresectable or 
metastatic melanoma, metastatic non-small cell lung can-
cer, advanced head and neck squamous cell carcinoma, 
advanced or metastatic gastric or gastroesophageal 
junction cancer, microsatellite instability-high cancer, 
locally advanced or metastatic urothelial cancer, recurrent 
or metastatic cervical cancer, refractory classical Hodgkin 
lymphoma, and refractory primary mediastinal large B 
cell lymphoma.
PD-L1 inhibitors 
Atezolizumab: Indicated for advanced or metastatic 
non-small cell lung cancer and advanced or metastatic 
urothelial cancer.
Avelumab: Indicated for advanced or metastatic uro-
thelial cancer and metastatic Merkel cell cancer.
Durvalumab: Indicated for advanced or metastatic 
urothelial cancer, as well as unresectable and stage Ⅲ 
non-small lung cancer.
IMMUNE-RELATED ADVERSE EVENTS
Immune-related adverse events (IRAE) can occur due 
to the use of checkpoint inhibitors. Inflammatory side ef-
fects generally involve the skin, gastrointestinal tract, liver 
and endocrine glands. The cardiovascular, pulmonary, 
renal, hematological and musculoskeletal system are 
less commonly involved. IRAE are more severe following 
administration of CTLA-4 inhibitors in comparison to PD-1 
or PD-L1 inhibitors. The time of onset of IRAE is generally 
1-6 mo after administration of checkpoint inhibitors[30]. 
Here, we will be mainly discussing the gastrointestinal, 
hepatic and pancreatic side effects of checkpoint inhi-
bitors.
Immune-related adverse events are classified accor-
ding to the National Cancer Institute’s Common Termi-
nology Criteria for Adverse Events (AE), version 3.0[31]. 
Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: 
Severe AE; Grade 4: Life-threatening or disabling AE; 
Grade 5: Death related to AE.
Gastrointestinal
Diarrhea is the most common gastrointestinal side effect 
after administration of checkpoint inhibitors. Diarrhea 
occurs in 27%-31% of cases following CTLA-4 inhibitor 
therapy[32] and less than 4% of cases following anti-
PD-1 and anti-PD-L1 therapy[33]. Diarrhea varies from 
mild to severe in intensity. Immune-mediated mild to 
severe colitis, colon perforation and even death can oc-
cur following checkpoint inhibitor therapy[34,35]. Severe 
colitis can occur in 5% of cases following CTLA-4 inhibitor 
therapy and less than 2% of cases following anti-PD-1 
therapy. Colitis may mimic Crohn’s colitis or ulcerative 
colitis, and can be associated with intra-abdominal ab-
scess, anal fissure and fistula[36]. Pembrolizumab-induced 
collagenous colitis and lymphocytic colitis have also been 
reported in the literature[37,38]. 
Management 
Mild diarrhea or grade Ⅰ diarrhea with stool frequency 
less than 4 times per day can be managed conservatively 
without discontinuing checkpoint inhibitors. Stool for ova, 
parasites, giardia antigen, stool culture and C. difficile 
toxin should be sent to evaluate for any underlying infec-
tion. Patient should be given adequate oral hydration and 
anti-diarrheal agents. If diarrhea still persists for 5-7 d or 
worsens, patients should be treated similar to cases of 
moderate diarrhea.
Moderate diarrhea or grade Ⅱ diarrhea with stool 
frequency between 4-6 times per day should be managed 
by discontinuation of checkpoint inhibitors, by ruling out 
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Figure 1  Schematic diagram of checkpoint inhibitors.
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control of diarrhea, start tapering corticosteroid over 1-2 
mo plus trimethoprim-sulfamethoxazole as prophylaxis; 
(2) no clinical improvement → Manage as grade Ⅲ or 
Ⅳ diarrhea. Grade Ⅲ or Ⅳ diarrhea: hospitalization, 
parenteral hydration, parenteral corticosteroid, abdominal 
CT and colonoscopy: (1) Clinical response: continue ste-
roid for a month and taper; (2) no clinical response: anti-
TNF therapy.
Hepatic
Checkpoint inhibitors can cause immune-mediated 
hepatitis in less than 5% of cases receiving these medi-
cations[46]. Although this can occur anytime while the 
patient is on checkpoint inhibitor therapy, it occurs most 
commonly 6-7 wk after the onset of therapy[47]. Most of 
the time, patients remain asymptomatic with elevated 
serum transaminases. Sometimes, the hepatitis can be 
more severe, with patients presenting with fever, ma-
laise, fatigue, hepatomegaly and hyperbilirubinemia. 
Acute viral hepatitis (HAV, HBV, HCV, EBV, CMV) and auto-
immune hepatitis need to be excluded by serology and 
liver biopsy[48]. Predominant hepatic parenchymal injury 
with panlobular hepatitis or predominant bile duct injury 
with mononuclear cell infiltration around proliferated bile 
ductules can be seen after checkpoint inhibitor therapy[49]. 
It is sometimes difficult to distinguish autoimmune hepa-
titis from drug-induced hepatitis. In autoimmune hepa-
titis, intra-acinar and portal plasma cells with rosette 
formation and emperiopolesis are prominent, whereas 
neutrophilic infiltration is more commonly seen in drug-
induced liver injury[50].
Management[51]
Grade 1 immune-mediated hepatitis: patient is asymp-
tomatic or mildly symptomatic, but laboratory studies 
show AST/ALT: < 2.5 × ULN (upper limit of normal) 
and total bilirubin: < 1.5 × ULN. Treatment: continue 
checkpoint inhibitor therapy, but monitor LFT.
Grade 2 immune-mediated hepatitis: patient is 
symptomatic (fever, malaise, fatigue) and laboratory 
studies show AST/ALT: 2.5-5 × ULN and total bilirubin: 
1.5-3 × ULN. Treatment: (1) hold checkpoint inhibitor 
therapy; (2) viral hepatitis (HAV, HBV, HCV, HDV, CMV, 
EBV, HSV, VZV), autoimmune hepatitis and drug-induced 
hepatitis need to be ruled out[46]; (3) prednisone 1 mg/
kg per day, taper the dose when patient’s symptoms 
improve; and (4) if symptoms do not improve after 48 
h, alternate immunosuppressive agents like tacrolimus, 
mycophenolate mofetil or cyclophosphamide need to be 
considered.
Grade 3 or 4 immune-mediated hepatitis: patient is 
symptomatic as mentioned above, and laboratory studies 
show: AST/ALT: > 5 × ULN; total bilirubin: > 3 × ULN. 
Treatment: (1) hold checkpoint inhibitors; (2) intravenous 
solumedrol 2-4 mg/kg per day. Taper the dose when 
patient’s symptoms improve; and (3) if symptoms do 
not improve after 5-7 d, tacrolimus 0.10-0.15 mg/kg 
per day should be added. Alternative agents include 
infection by sending stool samples as mentioned above, 
by giving adequate oral hydration and by administering 
empiric treatment with oral corticosteroid (prednisone 
1 mg/kg per day) with close clinical follow-up[39]. 
Colonoscopy is not required if the patient responds to 
the above measures. After 2-5 d control of diarrhea, 
prednisone should be slowly tapered over a 1-2 mo 
period of time. Trimethoprim-sulfamethoxazole should 
be given as a prophylaxis against opportunistic infection 
during the tapering period[40].
If the patient does not respond to the conservative 
measures or if the patient has severe diarrhea, i.e., 
grade Ⅲ or Ⅳ diarrhea, with stool frequency more than 
6 times per day with severe and persistent abdominal 
pain, fever, rectal bleeding or ileus, intravenous hydration 
and intravenous steroid (methylprednisone 1-2 mg/kg 
per day) should be started[41]. Antidiarrheal agents 
like loperamide and lomotil (diphenoxylate/atropine) 
should be avoided. Abdominal CT (computerized axial 
tomography) should be done to assess the severity 
and complications of colitis (perforation and peritonitis). 
Colonoscopy or flexible sigmoidoscopy should be done 
not only to evaluate the severity and extent of colitis, 
but also to take random and targeted colon biopsies to 
rule out underlying cytomegalovirus (CMV) infection[35]. 
CMV colitis is diagnosed by characteristic histology 
(owl’s eye intranuclear inclusion bodies), CMV biopsy 
PCR (polymerase chain reaction) or CMV biopsy viral 
culture[42]. Colonoscopic findings may include loss of 
vascular markings, erythema, congestion, friability, 
ulcerations and spontaneous bleeding. The severity of 
diarrhea may not correlate with the colonoscopic or histo-
logical findings.
Treatment should be continued until there is signifi-
cant improvement of diarrhea, i.e., grade 0-1. If there is 
a clinical response to corticosteroids, it is recommended 
to continue treatment for a month and then slowly 
taper. If the patient’s diarrhea is refractory to steroids, or 
colonoscopy shows severe colitis, multiple colon ulcers 
or pancolitis, anti-TNF therapy like Infliximab (5 mg/kg 
every 2 wk) or anti-integrin therapy like Vedolizumab 
(300 mg 0, 2, 6 wk) should be added[43-45]. Concomitant 
bacterial, viral or Clostridium difficile infection should 
be treated simultaneously. Following resolution of symp-
toms, checkpoint inhibitors can be restarted if the bene-
fits outweigh the risks, and if the daily dose of prednisone 
can be reduced to less than 10 mg per day without any 
other immunosuppressive medication.
Summary of diarrhea management 
Diarrhea onset approximately 6 wk after checkpoint 
inhibitor therapy: assess severity of diarrhea and rule out 
infection by sending stool samples → Grade Ⅰ diarrhea: 
conservative treatment with oral hydration and anti-
diarrheal agents → Persistence of diarrhea after 5-7 d 
→ Manage as grade Ⅱ diarrhea. Grade Ⅱ diarrhea: stop 
checkpoint inhibitor, start oral corticosteroid and continue 
oral hydration: (1) Clinical improvement → 2-5 d after 
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mycophenolate mofetil or cyclophosphamide. 
Pancreatic
Immune-mediated pancreatitis with pancreatic insuf-
ficiency has been reported a few months after initiation of 
checkpoint inhibitor therapy[52]. Asymptomatic elevations 
of amylase and lipase can occur without fulfilling the 
diagnostic criteria of acute pancreatitis. As the clinical 
significance of this lab abnormality is unknown, routine 
measurement of serum amylase and lipase is not recom-
mended[53]. However, if the patient is symptomatic 
with abdominal pain or nausea, immune-mediated pan-
creatitis should be considered by checking amylase and 
lipase levels and performing imaging studies.
Management
Intravenous methylprednisolone (1 mg/kg per day) for a 
few days, followed by oral prednisone (1 mg/kg per day). 
Taper the dose when patient symptoms improve.
Pancreatic enzyme supplementation should be given 
if there is evidence of pancreatic insufficiency (fecal 
elastase < 15 μg/g of feces).
CONCLUSION
Checkpoint inhibitors are novel forms of immunotherapy 
administered by oncologists. Although they are extremely 
useful in various advanced and metastatic malignancies, 
they can cause multiple side effects. Gastroenterologists 
need to be aware of the various gastrointestinal, hepatic 
and pancreatic side effects that can be fatal if not man-
aged early. Prompt recognition of these side effects, 
administration of systemic immunosuppressive therapy 
and supportive care could improve the clinical outcome 
without affecting the benefit of checkpoint inhibitors. 
Multidisciplinary teams should be involved in the man-
agement of these side effects. As new checkpoints are 
being discovered and new checkpoint inhibitors are 
being developed, patients will be experiencing new IRAE. 
Management of those IRAE will improve as we gather 
more experience using new checkpoint inhibitors.
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